Cisplatin (CDDP)-induced acute toxicity in an experimental model of hepatic fibrosis

Journal of Toxicological Sciences

Volumn 32, Issue 3, 2007, Pages 311-319

  Miyamoto, Yohei ^a   Shimada, Kaoru ^a   Sakaguchi, Yuka ^a   Miyamoto, Mari ^a  

^a TORAY INDUSTRIES INC   (Japan)

Author keywords

Acute toxicity; Cisplatin (CDDP); CYP2E1; GSH; Hepatic fibrosis; Rats

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILE ACID; CHOLESTEROL; CISPLATIN; CREATININE; GLUCOSE; LACTATE DEHYDROGENASE; TRIACYLGLYCEROL;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE ACID BLOOD LEVEL; CELL DEGENERATION; CELL PROLIFERATION; CELL VACUOLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER NECROSIS; LIVER TOXICITY; MALE; NEPHROTOXICITY; NONHUMAN; RAT; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

RATTUS; SUIDAE;

EID: 34548649549     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.32.311     Document Type: Article

References (23)

1. Ballardini, G., Faccani, A., Fallani, M., Berti, S., Vasi, V., Castaldini, C., Biagini, G., Garbisa, S. and Bianchi, F.B. (1985): Sequential behaviour of extracellular matrix glycoproteins in an experimental model of hepatic fibrosis. Virchows Arch. B. Cell Pathol. Incl. Mol. Pathol., 49, 317-324.
2. Bhunchet, E. and Wake, K. (1992): Role of mesenchymal cell populations in porcine serum-induced rat liver fibrosis. Hepatology., 16, 1452-1473.
3. Davis, S., Kessler, W., Haddad, B. M. and Maesaka, J. K. (1980): Acute renal tubular dysfunction following cis-dichlorodiammine platinum therapy. J. Med., 11, 133-141.
4. Dentino, M., Luft, F.C., Yum, M.N., Williams, S.D. and Einhorn, L.H. (1978): Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer, 41, 1274-1281.
5. Fujiwara, K., Ogata, I., Ohta, Y., Hayashi, S., Mishiro, S., Takatsuki, K., Sato, Y., Yamada, S., Hirata, K., Oka, H., Oda, T., Kawaji, H., Matsuda, S., Niiyama, Y. and Tsukada, R. (1988): Decreased collagen accumulation by a prolyl hydroxylase inhibitor in pig serum-induced fibrotic rat liver. Hepatology, 8, 804-807.
6. Hardaker, W.T., Stone, R.A. and McCoy, R. (1974): Platinum nephrotoxicity. Cancer, 34, 1030-1032.
7. Kim, S.H., Hong, K.O., Chung, W.Y., Hwang, J.K. and Park, K.K. (2004): Abrogation of cisplatin-induced hepatotoxicity in mice by xanthorrhizol is related to its effect on the regulation of gene transcription. Toxicol. Appl. Pharmacol., 196, 346-355.
8. Kitamura, K., Yasoshima, A., Iwasaki, H. O., Kojima, A., Doi, K. and Okaniwa, A. (1984): Hepatic fibrosis produced in rats by repeated intraperitoneal injections of swine serum. Jpn. J. Vet. Sci., 46, 265-271.
9. Kobayashi, K., Sugiyama, Y. and Kitajima, S. (1996): Elementary biostatistcal analysis for toxicological data '96, pp.20-24, An-Pyo Center, Japan.
10. Komorizono, Y., Kohara, K., Oketani, M., Maeda, M., Shibathou, T., Shigenobu, S., Hiramine, Y., Yamasaki, N., Arima, T. and Kazuaki, I. (2003): Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study. Dig. Dis. Sci., 48, 877-881.
11. Lu, Y. and Cederbaum, A.I. (2006): Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicol. Sci., 89, 515-523.
12. Macleod, P.M., Tyrell, C.J. and Keeling, D.H. (1988): The effect of cisplatin on renal function in patients with testicular tumors. Clin. Radiol., 39, 190-192.
13. Matsumura, Y., Sakaida, I., Uchida, K., Kimura, T., Ishihara, T. and Okita, K. (1997): Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation. J. Hepatol., 27, 185-192.
14. Ramos, S.G., Montenegro, A.P., Goissis, G. and Rossi, M.A. (1994): Captopril reduces collagen and mast cell and eosinophil accumulation in pig serum-induced rat liver fibrosis. Pathol. Int., 44, 655-661.
15. Rubin, E., Hutterer, F. and Popper, H. (1968): Experimental hepatic fibrosis without hepatocellular regeneration. A kinetic study. Am. J. Pathol., 52, 111-120.
16. Sakaida, I., Hironaka, K., Uchida, K., Suzuki, C., Kayano, K. and Okita, K. (1998a): Fibrosis accelerates the development of enzyme-altered lesions in the rat liver. Hepatology, 28, 1247-1252.
17. Sakaida, I., Uchida, K., Matsumura, Y. and Okita, K. (1998b): Interferon gamma treatment prevents procollagen gene expression without affecting transforming growth factor-beta1 expression in pig serum-induced rat liver fibrosis in vivo. J. Hepatol., 28, 471-479.
18. Sangro, B., Rios, R., Bilbao, I., Beloqui, O., Herrero, J. I., Quiroga, J. and Prieto, J. (2002): Efficacy and toxicity of intra-arterial cisplatin and etoposide for advanced hepatocellular carcinoma. Oncology, 62, 293-298.
19. Sun, M.A., Wang, B.E., Annoni, G., Degli Esposti, S., Biempica, L. and Zern, M.A. (1990): Two rat models of hepatic fibrosis. A morphologic and molecular comparison. Lab. Invest., 63, 467-475.
20. Tanioka, H., Tsuji, A., Morita, S., Horimi, T., Takamatsu, M., Shirasaka, T., Mizushima, T., Ochi, K., Kiura, K. and Tanimoto, M. (2003): Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res., 23, 1891-1897.
21. 2-microglobulin-uria during cisplatinum treatment. Eur. J. Clin. Pharmacol., 29, 313-318.
22. Tsukamoto, H. (1993): Oxidative stress, antioxidants, and alcoholic liver fibrogenesis. Alcohol, 10, 465-467.
23. Wada, S., Kato, T., Mutai, M., Ozaki, K., Yamaguchi, S., Kim, D.J., Baba-Toriyama, H., Asamoto, M., Ito, N. and Tsuda, H. (1996): Modifying influence of swine-serum-induced liver fibrosis on development of preneoplastic lesions in rat liver. Jpn. J. Cancer Res., 87, 240-246.